Is Solventum (SOLV) Fairly Valued On Raised 2026 Guidance Despite Debt And Cost Headwinds?

Solventum (SOLV) drew fresh investor attention after management raised its adjusted earnings guidance and organic sales growth outlook for 2026, while also emphasizing cost reductions, debt pressures, and raw material cost headwinds.

That guidance update comes after a period of steady share price gains, with Solventum’s 90 day share price return of 11.5% and year to date share price return of 16.3% supported by the stronger operating story. The 1 year total shareholder return of 28.71% indicates that momentum has been building as investors reassess both the growth outlook and the balance of risks around debt and input costs.

Compare Solventum’s setup with a curated group of healthcare stocks showing solid fundamentals and resilient balance sheets by scanning our list of solid balance sheet and fundamentals (52 results).

For Solventum, the recent share price climb and higher guidance both point to a stronger operating story, yet shifting sentiment around debt and input costs is clearly in play. How does that balance show up in today’s valuation?

Most Popular Narrative: 1.3% Undervalued

Solventum’s most followed valuation narrative puts fair value at $93.15 compared with the last close of $91.90, which points to only a slight gap and puts the focus firmly on the assumptions behind that figure.

Execution of multi year operational streamlining and ERP implementations post spin off from 3M is progressing ahead of plan, with full completion expected by 2027. As separation related costs drop off, this should enhance free cash flow, operating margin, and ultimately net earnings.

Read the complete narrative.

Want to see what underpins that fair value for Solventum? The narrative leans on modest revenue expansion, lower long run margins, and a richer future earnings multiple.

Result: Fair Value of $93.15 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Solventum’s thesis still hinges on smooth execution of the 3M separation and ERP rollout, while the HIS carve out could introduce cost, timing, and earnings surprises.

Find out about the key risks to this Solventum narrative.

Next Steps

With Solventum showing both appealing strengths and clear concerns, it makes sense to review the details yourself and move quickly to form your own view using 3 key rewards and 3 important warning signs.

Looking for more investment ideas beyond Solventum?

If Solventum has sharpened your focus on quality, do not stop here. Use the Simply Wall Street Screener to quickly surface fresh, data driven stock ideas.

• Target potential bargains that pair strong fundamentals with attractive pricing by scanning a curated set of companies using the 54 high quality undervalued stocks.
• Strengthen the defensive side of your portfolio by reviewing a 75 resilient stocks with low risk scores that filters for resilience and lower overall risk profiles.
• Spot future contenders early by checking a 20 high quality undiscovered gems that highlights quality businesses which may not yet be widely followed.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com